Glooko said this week that it inked an agreement with nonprofit research organization T1D Exchange to use Glooko’s diabetes management solution to incorporate anonymized diabetes data into the TID Exchange Quality Improvement Collaborative (QIC).
Mountain View, Calif.-based Glooko said that the QIC is a data platform and learning collaborative made up of 11 U.S. diabetes centers, and that it believes the agreement “will result in one of the richest patient data sets to study T1D and drive advances in treatment and care.”
“The T1D Exchange partnership with Glooko will provide clinicians with an entirely new level of insight by giving them for the first time access to analyzed raw device data linked with EMR data. We will be able to use these comprehensive data analytics to ultimately expand outcome measures for T1D and move beyond A1c, informing our effort and mission to improve outcomes for people living with the disease,” T1D Exchange interim COO Rebecca Parkes said in a press release.
The T1D Exchange’s QIC researches all aspects of how people with T1D and their healthcare professionals measure, treat and manage diabetes, Glooko said.
“T1D Exchange offers one of the best resources available today to diabetes researchers working to make a real difference in the life of people with T1D. The team at Glooko is excited to have the privilege of enhancing the value of that resource by making it possible to securely integrate peoples’ anonymized diabetes device data into the T1D Exchange data platform, and we look forward to partnering with the team at T1D Exchange to make that happen,” Glooko CEO Russ Johannesson said in a prepared statement.
As part of the agreement, Glooko’s platform will now provide the means to transfer diabetes device data of patients treated at medical centers in the Q1C to the T1D Exchange QIC data platform as de-identified data.
Diabetes centers participating members of the QIC include theBarbara Davis Center for Diabetes/Children’s Hospital Colorado, Baylor College of Medicine/Texas Children’s Hospital, Cincinnati Children’s Hospital, C.S. Mott Children’s Hospital, U of Michigan Hospitals-Michigan Medicine, The Joslin Diabetes Center – SUNY Upstate Medical University, Lucile Packard Children’s Hospital/Stanford, Nationwide Children’s Hospital, Penn Rodebaugh Diabetes Center, Penn Medicine, University of Missouri, Kansas City/Children’s Mercy Kansas City and Wayne State University, Glooko said.
“Healthcare data are plenteous, but diversity, volume and formatting make it challenging for people with T1D and their medical teams to use it for decision-making. The partnership between Glooko and T1D Exchange will organize raw, patient-generated data and facilitate linkage with healthcare records—a novel approach in diabetes. At the level of the individual, we will make better decisions; for the population, we will understand trends and be able to track a broader range of outcomes,” Dr. Todd Alonso of the Barbara Davis Center, University of Colorado said in preapred remarks.
Yesterday, Companion Medical said that it inked a partnership deal with Glooko to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data management system and mobile application.
